Menarini Asia-Pacific

What Menarini Asia-Pacific does

Menarini Asia-Pacific is the regional operating arm of Italy's Menarini Group, a privately-held biopharmaceutical company with 135+ years of history. Headquartered in Singapore, the company provides end-to-end pharmaceutical commercialization capabilities across 13 key Asia-Pacific markets (Australia, New Zealand, China, Hong Kong, India, Indonesia, Korea, Malaysia, Philippines, Taiwan, Thailand, Vietnam, and Singapore). Its operations span three core divisions: Pharmaceuticals (covering eight therapeutic areas—Cardiometabolic, Men's Health, Pain, Aesthetic Medicine, Dermatology, Gastroenterology, Allergy & Respiratory, and Oncology), Consumer Healthcare (Dermatology, Respiratory Health, Active Aging, Overall Wellbeing), and Diagnostics (Laboratory and Advanced Diagnostics, including the CELLSEARCH circulating tumor cell platform).

The company manages a portfolio of 200+ proprietary and licensed healthcare brands, combining internally developed products with territorial licensing rights from global originator pharma companies including Astellas (Smyraf), Daiichi Sankyo (LIXIANA, TARLIGE), Eli Lilly (Cialis in China), Pharmacosmos (MonoFer), Gilead (Ranexa), Mitsubishi Tanabe (Spedra), and SciClone (Vaborem). Notable proprietary assets include ORSERDU (elacestrant), a first-in-class SERD for ESR1-mutated breast cancer that received FDA and EC approval in 2023. Manufacturing is conducted through PT Menarini Indria Laboratories in Indonesia (ISO 13485, GMP, Halal certified), and R&D is anchored by the Menarini Biomarkers Singapore research center.

Revenue is generated through direct sales to hospitals, healthcare providers, and pharmacies via in-country field sales teams, combined with licensing royalties and distribution arrangements. Key customer segments are hospitals and healthcare providers (primary), healthcare professionals (prescribers), and patients/consumers (consumer health). The company employs an omni-channel marketing distribution strategy combining field sales, digital channels, content marketing, and brand initiatives. Its go-to-market spans enterprise field sales for hospital/prescription products, channel partners for licensing arrangements, and direct-to-consumer engagement for consumer health products. Strategic priorities are reflected in active M&A (Stemline Therapeutics $677M in 2020, Cialis China rights in 2021, CELLSEARCH from Janssen in 2016) and ongoing licensing deals to expand therapeutic and geographic reach.

Name

Menarini Asia-Pacific

Legal name

A. Menarini Asia-Pacific Holdings Pte. Ltd.

Website

https://menariniapac.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Menarini Asia-Pacific is the Singapore-headquartered Asia-Pacific arm of Italy's Menarini Group, commercializing 200+ prescription, consumer health, and diagnostics brands across 13 APAC markets through direct sales and licensing partnerships with hospitals, healthcare providers, and patients.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Men’s Health (OTC Urologic & Sexual Health) (HLAIADAK), Hand & Body Care (Lotions, Creams, Body Oils) (CRADANAC), Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF)

Keywords

• Pharmaceutical products
• Prescription medicines
• Consumer healthcare
• Medical diagnostics
• Therapeutic brands

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices16 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription pharmaceutical products and consumer health products through direct presence in 13 Asia-Pacific markets. Revenue generated from hospitals, healthcare providers, pharmacies, and direct to patients.
2. Licensing and Distribution Agreements: Revenue from licensing agreements for commercializing proprietary or partnered products in specific territories (e.g., LIXIANA®, Smyraf®, MonoFer®).

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Menarini Asia-Pacific develops, licenses, and commercializes pharmaceutical products, consumer health brands, and diagnostic solutions across 13 Asia-Pacific markets. It manages over 200 proprietary and licensed healthcare brands spanning prescription medicines (cardiovascular, oncology, men's health, dermatology, gastroenterology, pain, allergy/respiratory, aesthetic medicine) and consumer health products (scar care, immune support, respiratory health).

Product overview

Menarini Asia-Pacific is a leading biopharmaceutical company operating three core divisions: Pharmaceuticals, Consumer Healthcare, and Diagnostics. The company manages over 200 high-quality proprietary and licensed healthcare brands from renowned bio-pharmaceutical companies. The Pharmaceuticals division covers eight therapeutic areas (Cardiometabolic, Men's Health, Pain, Aesthetic Medicine, Dermatology, Gastroenterology, Allergy & Respiratory, and Oncology). Consumer Healthcare offers OTC products and supplements including Dermatix®, Sambucol®, and Kamillosan M. The Diagnostics division provides Laboratory and Advanced Diagnostics solutions. The company operates manufacturing facilities in Indonesia through PT Menarini Indria Laboratories and a biomarker research center in Singapore. With a direct presence in 13 key APAC markets, Menarini offers end-to-end capabilities from clinical development through product commercialization and lifecycle management.

Differentiator

Problem solved

Functional benefit

Brands

• Dermatix: Scar treatment and skin care brand
• Sambucol
• Kamillosan M
• Transpulmin
• ORSERDU (Elacestrant)
• Menarini Biomarkers Singapore

Products and services

• ORSERDU (Elacestrant) A selective estrogen receptor degrader (SERD) approved for treatment of ER+, HER2- locally advanced or metastatic breast cancer with activating ESR1 mutation; first and only treatment specifically indicated for ESR1 mutations. Sold to hospitals and oncology specialists.
• NEXPOVIO (Selinexor) Treatment for multiple myeloma after at least one prior therapy, sold to oncology specialists and hospitals.
• Vaborem (Meropenem/Vaborbactam) Antibiotic treatment for antimicrobial resistant infections, licensed from SciClone for development and commercialization in China. Sold to hospitals.
• Cialis (Tadalafil) Men's health product for erectile dysfunction, acquired from Lilly to strengthen Menarini Asia-Pacific's men's health portfolio in China. Sold to healthcare professionals and pharmacies.
• Smyraf (Igacitinib) Rheumatoid arthritis treatment licensed from Astellas for commercialization in Taiwan and select South-East Asian markets.
• TARLIGE (Mirogabalin) Pain management medication licensed from Daiichi Sankyo for commercialization in Singapore, Malaysia, and the Philippines.
• LIXIANA (Edoxaban) Direct oral anticoagulant licensed from Daiichi Sankyo for commercialization in the Philippines, Malaysia, and Singapore.
• Spedra (Avanafil) Men's health product licensed from Mitsubishi Tanabe Pharma Corporation for commercialization in 10 Asia-Pacific countries.
• Asacol Anti-inflammatory bowel medication; Tillotts and Menarini received regulatory approval for Asacol 400 and 800 mg tablets in China.
• Ranexa (Ranolazine) Anti-anginal medication licensed from Gilead Sciences for commercialization in 50 new countries.
• Dermatix Scar treatment gel brand with Dermatix Ultra and Dermatix Acne Scarring Solution variants; multiple award-winning skincare product sold through pharmacies and retailers.
• Sambucol Black elderberry supplement brand for immune support, available in various formats including gummies; sold through pharmacies and retail channels.
• Kamillosan M Chamomile-based healthcare product sold through consumer health channels.
• CALECIM Stem cell-based skincare product line partnered with Menarini Asia-Pacific for expansion across the region.
• MonoFer Iron replacement therapy; partnership with Pharmacosmos grants Menarini distribution rights for this product in Singapore and Malaysia.
• CELLSEARCH Circulating tumor cell tracking technology for cancer diagnostics, sold to hospitals and diagnostic laboratories.

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and major.

• PharmacosmoscoreChannel Partner/ Reseller/ Distributor · 1 January 2024Partnership to expand MonoFer® (iron replacement therapy) distribution to Singapore and Malaysia. Pharmacosmos grants Menarini distribution rights for their iron product in these key Asia-Pacific markets, strengthening Menarini's presence in the iron deficiency treatment space.
• AstellascoreOEM/ Whitelabel/ Licensing Partner · 1 January 2023Exclusive licensing agreement granting Menarini rights to commercialize Smyraf® (biologic treatment) in Taiwan and select South-East Asian markets. Astellas provides product licensing while Menarini leverages its regional distribution network and market presence.
• Daiichi SankyocoreOEM/ Whitelabel/ Licensing PartnerLicensing agreement for LIXIANA® (anticoagulant), expanding Menarini's cardiovascular portfolio across Asia-Pacific markets. Menarini commercializes the product in designated territories using its regional infrastructure.
• Eli LillymajorStrategic or Co-development PartnerAcquisition of Cialis® (tadalafil) from Lilly in China, representing a significant expansion of Men's Health portfolio in the Chinese market. Transfer of product rights and commercialization responsibilities.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Astellas Pharma: Japanese pharmaceutical major and direct licensing partner of Menarini Asia-Pacific for Smyraf. Comparable as an originator pharma with significant APAC commercialization presence across therapeutic areas including oncology, urology, and immunology.
• Daiichi Sankyo: Japanese originator of LIXIANA and TARLIGE, both licensed to Menarini for APAC commercialization. Comparable as a Japanese-headquartered innovator pharma with global cardiovascular and pain portfolios, distributing through regional partners in markets where Menarini operates.
• Otsuka Pharmaceutical: Japanese pharma with established APAC commercialization in CNS, oncology, and consumer health (including dermatology). Comparable mid-size innovator model with regional licensing partnerships and consumer health brand building similar to Menarini.
• Servier Asia: French privately-held pharma with direct APAC presence in oncology, cardiometabolic, and immunology — overlapping directly with Menarini's cardiometabolic and oncology therapeutic areas. Closest comparable as a private mid-sized multinational with similar geographic and therapeutic footprint.
• Eisai Asia: Japanese-headquartered pharma with established APAC commercialization in oncology, neurology, and consumer health. Comparable therapeutic mix and a long-standing model of partnering with regional distributors for market access across China and Southeast Asia.

Broad incumbents

• Takeda Pharmaceutical: Large Japanese-headquartered global pharmaceutical company with deep direct presence across the same 13 APAC markets where Menarini operates. Overlaps in specialty therapeutics, oncology, gastroenterology, and rare disease — a broad incumbent competing for the same hospital and prescriber relationships.
• Bayer Pharmaceuticals Asia: Global pharma major with established APAC presence across cardiovascular, women's health, and consumer health. Comparable in combining prescription pharma with OTC/consumer health brands, much like Menarini's three-division structure.
• Sanofi Asia: Global pharma and consumer healthcare leader with extensive APAC operations across specialty care, vaccines, and consumer health. Comparable business mix of prescription drugs plus consumer health brands, distributed through similar hospital and pharmacy channels across the same geographies.
• AbbVie Asia: Global pharma major with significant APAC presence across immunology, oncology, neuroscience, and aesthetics (post-Allergan). Comparable as a broad specialty pharma with both prescription and consumer/medical aesthetics portfolios serving hospitals and consumers across APAC.

Regional players

• Lundbeck Asia: Danish-headquartered specialty pharma focused on CNS and rare diseases with strong APAC distribution through local partners. Comparable as a regional specialty operator relying on licensing arrangements for certain markets, similar to Menarini's distributed licensing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC6MvpVAvfIFtTm5Nnu2K0XQ
• LinkedInlinkedin.com/company/menarini-asia-pacific/mycompany/verification/?viewAsMember=true
• Instagraminstagram.com/menarini_ap

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Menarini Asia-Pacific